Atorvastatin/sitagliptin - Merck & Co.

Drug Profile

Atorvastatin/sitagliptin - Merck & Co.

Alternative Names: MK-0431E; sitagliptin/atorvastatin - Merck

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrazines; Pyrroles; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atherosclerosis; Diabetes mellitus

Most Recent Events

  • 19 Jun 2017 Merck terminates phase III trial in Diabetes mellitus in Germany, Bulgaria and Hungary due to business reasons (NCT01477853)
  • 13 Nov 2012 Discontinued - Phase-III for Atherosclerosis in Germany (PO)
  • 13 Nov 2012 Discontinued - Phase-III for Diabetes mellitus in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top